Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

Clinical trial NCT01121939 · COMPLETED

Trial details

NCT number: NCT01121939
Sponsor: SCRI Development Innovations, LLC
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Neuroendocrine Carcinoma

Start date: 2010-05-01
Primary completion: 2015-02-01
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.